1. The continuing burden of Rh disease 50 years after the introduction of anti-Rh(D) immunoglobin prophylaxis: call to action
- Author
-
Gerard H.A. Visser, Gian Carlo Di Renzo, Steven L. Spitalnik, Diogo Ayres-de-Campos, Maria Fernanda Escobar, Eytan Barnea, P.K. Shah, Anwar Nasser, Luc de Bernis, Luming Sun, Wanda Kay Nicholson, Isabel Lloyd, Salimah Walani, Gerhard Theron, and William Stones
- Subjects
medicine.medical_specialty ,fetal anemia ,Internationality ,hyperbilirubinemia ,Rho(D) Immune Globulin ,Disease ,isoimmunization ,Rh Isoimmunization ,blood groups ,Health Services Accessibility ,03 medical and health sciences ,0302 clinical medicine ,Fetal anemia ,prevention ,Pregnancy ,medicine ,alloimmunization ,hemolysis ,hemolytic disease of the fetus and newborn ,Rh disease ,Female ,Humans ,Immunologic Factors ,Prenatal Care ,Rh-Hr Blood-Group System ,030212 general & internal medicine ,Intensive care medicine ,030219 obstetrics & reproductive medicine ,biology ,business.industry ,Obstetrics and Gynecology ,Call to action ,biology.protein ,Severe morbidity ,Antibody ,business ,Perinatal Deaths - Abstract
Severe morbidity and death because of Rh disease have only been reduced by approximately 50% globally during the last 50 years, despite the advent of anti-Rh(D) immunoglobin prophylaxis, which has resulted in >160,000 perinatal deaths and 100,000 disabilities annually. This apparent failure to take appropriate preventive measures is of great concern. Thus, there is a great need to do much better. We wish to draw attention to the unnecessary continuing burden of Rh disease, to discuss some of the reasons for this failure, and to provide suggestions for a better way forward.
- Published
- 2019